Group 1 - The core business of the company includes providing life science reagents, instruments, consumables, and comprehensive technical services, with revenue composition being 77.94% from life science reagents, 16.11% from instruments and consumables, and 5.95% from technical services [1] - As of January 22, the company's financing balance is 57.40 million yuan, accounting for 2.03% of the market capitalization, indicating a high level compared to the past year [1] - The company reported a decrease in revenue of 6.24% year-on-year for the period from January to September 2025, with total revenue of 776 million yuan and a net profit attributable to shareholders of -15.08 million yuan, a significant decline of 207.11% [2] Group 2 - The number of shareholders decreased by 13.19% to 9,893 as of September 30, while the average circulating shares per person increased by 15.19% to 5,753 [2] - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders include a new shareholder, Nuoan Multi-Strategy Mixed A, holding 499,100 shares [3]
优宁维1月22日获融资买入547.05万元，融资余额5739.58万元